Effects of Zinc Supplementation on Endocrine Outcomes in Women with Polycystic Ovary Syndrome: a Randomized, Double-Blind, Placebo-Controlled Trial.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.

The current study was conducted to evaluate the effects of zinc supplementation on endocrine outcomes, biomarkers of inflammation, and oxidative stress in patients with polycystic ovary syndrome (PCOS).

Why It Was Studied

This study was a randomized double-blind, placebo-controlled trial.

Who Took Part

The study group was 8 women.

By PubMed's age tags, the people studied were teenagers and adults, women only.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

The women were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

Blinding on both sides kept the women and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.

The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.

What Was Measured

Topics PubMed links to this paper include Biomarkers, C-Reactive Protein, Cytokines, Dietary Supplements, Inflammation, Malondialdehyde and Oxidative Stress.

The authors tagged it with the keywords Polycystic ovary syndrome, Reproductive outcomes, Supplementation and Zinc.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 8 women.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2016 (Biological trace element research), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.